25th
September 2018 - Global
plasma protease C1-inhibitor treatment market is expected to grow at the
highest CAGR in the upcoming years. C1-inhibitor is also known as C1-INH and C1
esterase inhibitor. C1-INH’s deficiency is the genetic defect underlying
hereditary angioedema (HAE). Plasma protease C1-inhibitor concentrate is an
effective and safe treatment for acute hereditary angioedema (HAE) attacks. The
factors that play an important role in the growth of plasma protease
C1-inhibitor treatment industry are prevalence of rare diseases, novel
therapies, promising pipeline drugs, increasing investments in innovation of
inhibitor drugs, and rising awareness regarding HAE.
Growth drivers for the plasma protease C1-inhibitor treatment market are
rising practice of administering prophylactic treatment process for hereditary
angioedema (HAE) patients, increasing demand for administering drugs internally
among HAE patients, and new route for highly demand of C1-inhibitor drugs. This
market is segmented on the basis of drug class, dosage type, distribution
channel, and geography.
Browse Full
Research Report @ https://www.millioninsights.com/industry-reports/plasma-protease-c1-inhibitor-treatment-market
Based on drug class, the plasma protease C1-inhibitor treatment industry
is classified as C1-inhibitors, kallikrein inhibitor (kalbitor), selective
bradykinin B2 receptor antagonist (firazyr) and so on. The segment
“C1-inhibitor” is sub-divided into C1-esterase inhibitor, recombinant
inhibitor, and so on. Also, this segment held the highest market share in the
past few years as C1-inhibitor drugs are usually used for the treatment of
acute hereditary angioedema (HAE) and prophylaxis. Based on dosage type, the
plasma protease C1-inhibitor treatment market is classified as
liquid/injectable, lyophilized, and so on. The segment “lyophilized” held
highest share in the past few years due to rising practice of intravenous
administration of drugs for the treatment of HAE.
Based on distribution channel, the plasma protease C1-inhibitor treatment
industry is classified as hospital pharmacies, independent pharmacies &
outlets, and so on. Based on geography, the plasma protease C1-inhibitor
treatment industry is classified as North America (U.S., Canada), Latin America
(Brazil, Argentina, and Rest of Latin America), Europe (EU-5 Countries, BENELUX
countries, Rest of Europe), and Rest of World (Israel, Australia, Rest of world
countries).
Latin America and Asia Pacific are expected to control the lyophilized
segment positively due to growth in high demand for intravenous C1 esterase
inhibitor drugs market. Key players operating in the plasma protease
C1-inhibitor treatment market are Shire plc, Sanquin, CSL Limited, Vertec
Biosolvents, Somaiya Group, Pharming Group N.V., Yancheng Hongtai
Bioengineering and Huade Biological Engineering.
Request a Free Sample
Copy of This Report @ https://www.millioninsights.com/industry-reports/plasma-protease-c1-inhibitor-treatment-market/request-sample
Comments
Post a Comment